Lightchain Capital

Recent News

C4-logo-400
March 16, 2022

C4 Therapeutics Appoints Utpal Koppikar to Board of Directors

READ MORE
wugen-logo-400
March 15, 2022

Wugen Announces First Patient Dosed in Phase 1/2 Trial of WU-CART-007 for the Treatment of Patients with R/R T-ALL/LBL

READ MORE
wugen-logo-400
March 09, 2022

Wugen to Present Virtually at the Upcoming Oppenheimer 32nd Annual Healthcare Conference

READ MORE
C4-logo-400
March 09, 2022

C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma

READ MORE
C4-logo-400
March 03, 2022

C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022

READ MORE
NextRNA-Logo-FullColor-400
March 02, 2022

NextRNA: small molecules take on lncRNA-protein interactions

READ MORE
NextRNA-Logo-FullColor-400
March 01, 2022

NextRNA Launches with $56 Million in Funding to Bring Transformative Non-Coding RNA-Directed Medicines to Patients

READ MORE
NextRNA-Logo-FullColor-400
March 01, 2022

NextRNA Launches with $56 Million in Funding to Bring Transformative Non-coding RNA-directed Medicines to Patients

READ MORE
C4-logo-400
February 24, 2022

C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights

READ MORE

Contact Us

Lightchain Capital, LLC
PO Box 31729
St. Louis, MO 63131

 

LinkedIn

Submit

©2024 LIGHTCHAIN CAPITAL, LLC  All Rights Reserved | Privacy Policy
Website by Tidal Media Group